|
|
|
|
|
|
|
|
|
|
|
|
|
13.07.26 - 22:09
|
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on July 10, 2026, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 6,300 shares of common stock and 9,300 restricted stock units (“RSUs”) to 6 new employees under Mirum's 2020 Inducement Plan. The Compensation Committee of Mirum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price of $122.13 per share, which is equal to the closing price of Mirum's common stock on July 10, 2026, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date, and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continu...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15.06.26 - 15:45
|
Albireo Pharma: Sind diese Daten die Trendwende? (Sharedeals)
|
|
|
Winkt hier die nächste Zulassung? Aktionäre von Albireo Pharma (WKN: A2DF99) können sich über starke Studiendaten freuen. Eine Erweiterung des bestehenden Vertriebs in den nächsten Monaten ist damit realistisch geworden. Muss Wettbewerber Mirum Pharmaceuticals jetzt zittern? Albireo Pharma konzentriert sich in der Medikamentenentwicklung auf seltene Leberkrankheiten und kann mit Bylvay bereits ein global zugelassenes Vertriebsprodukt […]
The post Albireo Pharma: Sind diese Daten die Trendwende? first appeared on sharedeals.de....
|
|
|
|
|
11.06.26 - 22:06
|
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on June 10, 2026, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 10,100 shares of common stock and 13,350 restricted stock units (“RSUs”) to 8 new employees under Mirum's 2020 Inducement Plan. The Compensation Committee of Mirum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).Each stock option has an exercise price of $94.00 per share, which is equal to the closing price of Mirum's common stock on June 10, 2026, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date, and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continu...
|
|
|
|
|
04.06.26 - 14:06
|
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026 (Business Wire)
|
|
|
- Late-breaking rapid-fire presentation to include results from Cohort 1 of the placebo-controlled PROGRESS study evaluating zilurgisertib in fibrodysplasia ossificans progressiva (FOP)FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Incyte (Nasdaq: INCY) today announced that pivotal Phase 2 results from the PROGRESS study evaluating zilurgisertib, an investigational ALK2 inhibitor, in patients with fibrodysplasia ossificans progressiva (“FOP”) will be presented at ENDO 2026, the Endocrine Society's annual meeting, taking place June 13-16, 2026, in Chicago, Illinois.
The late-breaking rapid-fire presentation will include results from Cohort 1 of the placebo-controlled PROGRESS study, which enrolled patients 12 years of age and older and formed the basis of the New Drug Application (NDA) for zilurgisertib to the U.S. Food and Drug Administration (FDA).
In April 2026, Mirum entered into an exclusive license agreement with Incyte for worldwide right...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
